Vasopressin receptor antagonists for the treatment of hyponatremia: Systematic review and meta-analysis

American Journal of Kidney Diseases

Volumn 56, Issue 2, 2010, Pages 325-337

  Rozen Zvi, Benaya ^a,b   Yahav, Dafna ^a,b   Gheorghiade, Mihai ^c   Korzets, Asher ^a,b   Leibovici, Leonard ^a,b   Gafter, Uzi ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

hyponatremia; systematic review; Vasopressin receptor antagonists

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; LITHIUM; LIXIVAPTAN; SATAVAPTAN; TOLVAPTAN; UREA; VASOPRESSIN ANTAGONIST; 5 FLUORO 2 METHYL N (4 (5H PYRROLO(2,1 C) (1,4)BENZODIAZEPIN 10 (11H) YLCARBONYL) 3 CHLOROPHENYL)BENZAMIDE; 5-FLUORO-2-METHYL-N-(4-(5H-PYRROLO(2,1-C)-(1,4)BENZODIAZEPIN-10-(11H)-YLCARBONYL)-3-CHLOROPHENYL)BENZAMIDE; AZEPINE DERIVATIVE; BENZAMIDE DERIVATIVE; BENZAZEPINE DERIVATIVE; MORPHOLINE DERIVATIVE; SPIRO COMPOUND; VASOPRESSIN RECEPTOR;

CLINICAL TRIAL; DEMYELINATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; HYPERNATREMIA; HYPONATREMIA; HYPOTENSION; META ANALYSIS; ORTHOSTATIC HYPOTENSION; REVIEW; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; DRUG ANTAGONISM; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AZEPINES; BENZAMIDES; BENZAZEPINES; HUMANS; HYPONATREMIA; MORPHOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASOPRESSIN; SPIRO COMPOUNDS; TREATMENT OUTCOME;

EID: 77955906640     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.01.013     Document Type: Article

References (38)

1. R.W. Schrier, P. Gross, and M. Gheorghiade, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 20 2006 2099 2112
2. A. Upadhyay, B.L. Jaber, and N.E. Madias Epidemiology of hyponatremia Semin Nephrol 29 3 2009 227 238
3. C.C. Wu, L.K. Yeung, and W.S. Tsai, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis Clin Nephrol 65 1 2006 28 33
4. L. Klein, C.M. O'Connor, and J.D. Leimberger, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study Circulation 111 19 2005 2454 2460
5. L. De Luca, L. Klein, and J.E. Udelson, et al. Hyponatremia in patients with heart failure Am J Cardiol 96 12A 2005 19L 23L
6. M.C. Londono, M. Guevara, and A. Rimola, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation Gastroenterology 130 4 2006 1135 1143
7. D.A. Sica Hyponatremia and heart failure - pathophysiology and implications Congest Heart Fail 11 5 2005 274 277
8. A. Goldberg, H. Hammerman, and S. Petcherski, et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction Arch Intern Med 166 7 2006 781 786
9. A. Bhardwaj Neurological impact of vasopressin dysregulation and hyponatremia Ann Neurol 59 2 2006 229 236
10. B. Renneboog, W. Musch, X. Vandemergel, M.U. Manto, and G. Decaux Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits Am J Med 119 1 2006 e71 e78
11. M.R. Bekheirnia, and R.W. Schrier Pathophysiology of water and sodium retention: edematous states with normal kidney function Curr Opin Pharmacol 6 2 2006 202 207
12. R.W. Schrier Body water homeostasis: clinical disorders of urinary dilution and concentration J Am Soc Nephrol 17 7 2006 1820 1832
13. J.G. Verbalis, S.R. Goldsmith, A. Greenberg, R.W. Schrier, and R.H. Sterns Hyponatremia treatment guidelines 2007: expert panel recommendations Am J Med 120 11 suppl 1 2007 S1 S21
14. G.L. Robertson Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis Am J Med 119 7 suppl 1 2006 S36 S42
15. P. Gross Treatment of hyponatremia Intern Med 47 10 2008 885 891
16. G. Decaux, P. Mols, P. Cauchi, and F. Delwiche Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics Br Med J 290 6484 1985 1782 1783
17. M.G. White, and C.D. Fetner Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate N Engl J Med 292 8 1975 390 392
18. J.E. Brunner, J.M. Redmond, A.M. Haggar, D.F. Kruger, and S.B. Elias Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study Ann Neurol 27 1 1990 61 66
19. G. Decaux, A. Soupart, and G. Vassart Non-peptide arginine-vasopressin antagonists: the vaptans Lancet 371 9624 2008 1624 1632
20. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 7414 2003 557 560
21. J.P. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions version 5.0.1 [updated September 2008] 2008 The Cochrane Collaboration www.cochrane-handbook.org Accessed March 1, 2010
22. D. Follmann, P. Elliott, I. Suh, and J. Cutler Variance imputation for overviews of clinical trials with continuous response J Clin Epidemiol 45 7 1992 769 773
23. S.G. Thompson, and S.J. Sharp Explaining heterogeneity in meta-analysis: a comparison of methods Stat Med 18 20 1999 2693 2708
24. M.A. Konstam, M. Gheorghiade, and J.C. Burnett Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 12 2007 1319 1331
25. F. Wong, A.T. Blei, L.M. Blendis, and P.J. Thuluvath A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial Hepatology 37 1 2003 182 191
26. D. Zeltser, S. Rosansky, H. van Rensburg, J.G. Verbalis, and N. Smith Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia Am J Nephrol 27 5 2007 447 457
27. A. Soupart, P. Gross, and J.J. Legros, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist Clin J Am Soc Nephrol 1 6 2006 1154 1160
28. J. Rossi, M. Bayram, and J.E. Udelson, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial Acute Card Care 9 2 2007 82 86
29. P. Gines, F. Wong, H. Watson, S. Milutinovic, L.R. del Arbol, and D. Olteanu Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial Hepatology 48 1 2008 204 213
30. M. Gheorghiade, I. Niazi, and J. Ouyang, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial Circulation 107 21 2003 2690 2696
31. M. Gheorghiade, S.S. Gottlieb, and J.E. Udelson, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia Am J Cardiol 97 7 2006 1064 1067
32. J.K. Ghali, M.J. Koren, and J.R. Taylor, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia J Clin Endocrinol Metab 91 6 2006 2145 2152
33. D. Aronson, M. Mueller, K. Verbalis, and H. Krum Satavaptan, a vasopressin V2-receptor antagonist, in the treatment of dilutional hyponatremia [abstract] J Am Soc Nephrol 18 abstracts issue 2007 790A
34. D. Annane, G. Decaux, and N. Smith Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia Am J Med Sci 337 1 2009 28 36
35. A.L. Gerbes, V. Gulberg, and P. Gines, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial Gastroenterology 124 4 2003 933 939
36. G. Decaux, A. Soupart, M. Mueller, E. Finta, and S. Alfoldi Long-term satavaptan treatment and drug holiday in patients with SIADH [abstract] J Am Soc Nephrol 19 abstracts issue 2008 588A
37. P.H. Baylis The syndrome of inappropriate antidiuretic hormone secretion Int J Biochem Cell Biol 35 11 2003 1495 1499
38. M.J. Bradburn, J.J. Deeks, J.A. Berlin, and A. Russell Localio Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events Stat Med 26 1 2007 53 77